Levi & Korsinsky notifies investors that it has commenced an investigation into Prestige Consumer Healthcare Inc. (NYSE: PBH) concerning potential violations of the federal securities laws.
During the Q3 FY 2026 earnings call, CEO Ron Lombardi stated that Prestige Consumer Healthcare anticipated a 57% adjusted gross margin in Q4. Management further projected projected free cash flow of $245 million or more for the full year alongside an adjusted EPS of $4.54. When Q4 results were reported, adjusted gross margin came in at approximately 55.4%, full-year free cash flow totaled $228 million, and adjusted diluted EPS was only 4.38; all three missed Prestige’s internal projections. Separately, Prestige Consumer Healthcare completed a $150 million acquisition of Australian skin-care firm LaCorium during the period. The acquisition was not discussed on the Q3 earnings call and was absent from the forward guidance framework presented to investors. PBH shares declined sharply following the Q4 disclosure.
If you suffered a loss on your Prestige Consumer Healthcare Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





